Trials / Completed
CompletedNCT03699579
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.
Conditions
Timeline
- Start date
- 2019-02-22
- Primary completion
- 2019-06-23
- Completion
- 2019-06-23
- First posted
- 2018-10-09
- Last updated
- 2019-08-28
Locations
2 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03699579. Inclusion in this directory is not an endorsement.